AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Alkermes Plc (NASDAQ:ALKS)
31.3801 USD
-0.330 1.040%Sponsored Reports
Loading...
| Previous Close (in USD) | 31.71 |
|---|---|
| Change | -0.330 1.040% |
| 52 W H/L (in USD) | 32.880/22.900 |
| EBITDA (in USD) | 358.806M |
| PE Ratio | 13.36 |
| Volume | 698152 |
| Diluted Eps TTM | 2.29 |
| Total Assets (in USD) | 2136.223M |
|---|---|
| Total Liabilities (in USD) | 933.537M |
| Revenue TTM (in USD) | 1505.121M |
| Cash (in USD) | 457.469M |
| Market Cap (in USD) | 4,951.172 M |
| Revenue Per Share TTM | 9.032 |
| Gross Profit TTM (in USD) | 893.687M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Alkermes Plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Employees: 2100
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Richard F. Pops | Chairman & CEO | 1962 |
| 2. | Mr. Iain Michael Brown | Sr. VP & CFO | 1969 |
| 3. | Mr. Blair C. Jackson | Exec. VP & COO | 1973 |
| 4. | Mr. David Joseph Gaffin | Exec. VP, Chief Legal Officer, Chief Compliance Officer & Sec. | 1972 |
| 5. | Dr. Craig C. Hopkinson M.D. | Exec. VP of R&D and Chief Medical Officer | 1968 |
| 6. | Dr. Floyd E. Bloom M.D. | Founder | 1937 |
| 7. | Mr. Thomas Harvey | Chief Information Officer & Sr. VP of IT | NA |
| 8. | Ms. Sandra Coombs | Sr. VP of Corp. Affairs & Investor Relations | NA |
| 9. | Mr. Michael J. Landine | Sr. VP of Corp. Devel. & Chief Risk Officer | 1954 |
| 10. | Mr. Stephen Schiavo | Sr. VP of HR | NA |
Peers
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ZTS
Zoetis Inc |
-4.410 2.592% | 168.82 | 40.180 | 30.960 | 10.675 | 17.597 | 11.271 | 26.180 |
|
MKKGY
Merck KGaA ADR |
+0.070 0.266% | 26.32 | 21.250 | 14.925 | 3.099 | 2.143 | 3.605 | 12.978 |
|
MKGAF
MERCK Kommanditgesellschaft auf Aktien |
-3.050 2.298% | 130.195 | 21.730 | 14.948 | 3.159 | 2.147 | 3.562 | 12.822 |
|
TAK
Takeda Pharmaceutical Co Ltd ADR |
+0.105 0.702% | 14.97 | 32.670 | 11.534 | 0.011 | 0.874 | 0.018 | 0.069 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -167.304M | -39.306M | -96.537M | -197.056M | -126.967M |
| Minority Interest | - | - | - | - | - |
| Net Income | -158.267M | -48.169M | -110.861M | -196.62M | -139.311M |
| Selling General Administrative | 605.747M | 560.977M | 538.827M | 599.449M | 526.408M |
| Gross Profit | 893.687M | 569.838M | 465.852M | 477.729M | 492.448M |
| Reconciled Depreciation | 36.363M | 78.652M | 81.854M | 80.413M | 103.66M |
| Ebit | -142.265M | -26.66M | -112.427M | -162.078M | -99.128M |
| Ebitda | -96.151M | 11.488M | -52.371M | -106.896M | -26.762M |
| Depreciation And Amortization | 46.114M | 38.148M | 60.056M | 55.182M | 72.366M |
| Operating Income | -142.265M | -26.66M | -112.427M | -162.078M | -99.128M |
| Other Operating Expenses | 1254.06M | 1203.038M | 1151.183M | 1333.025M | 1193.402M |
| Interest Expense | 13.04M | 11.219M | 8.659M | 13.601M | 15.437M |
| Tax Provision | -9.037M | 8.863M | 14.324M | -0.436M | 12.344M |
| Interest Income | 7.629M | 2.408M | 6.96M | 13.976M | 9.238M |
| Net Interest Income | -5.411M | -8.811M | -1.699M | 0.375M | -6.199M |
| Income Tax Expense | -9.037M | 8.863M | 14.324M | -0.436M | 12.344M |
| Total Revenue | 1111.795M | 1173.751M | 1038.756M | 1170.947M | 1094.274M |
| Total Operating Expenses | 1035.952M | 599.125M | 578.279M | 639.807M | 591.576M |
| Cost Of Revenue | 218.108M | 603.913M | 572.904M | 693.218M | 601.826M |
| Total Other Income Expense Net | -25.039M | -12.646M | 15.89M | -34.978M | -27.839M |
| Net Income From Continuing Ops | -158.267M | -48.169M | -110.861M | -196.62M | -139.311M |
| Net Income Applicable To Common Shares | -158.267M | -48.169M | -110.861M | -196.62M | -139.311M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 2136.223M | 1963.978M | 2024.484M | 1949.73M | 1805.403M |
| Intangible Assets | 1.991M | 37.68M | 74.043M | 111.191M | 150.643M |
| Other Current Assets | 98.166M | 43.527M | 48.967M | 60.662M | 59.716M |
| Total Liab | 933.537M | 920.225M | 911.9M | 882.748M | 719.961M |
| Total Stockholder Equity | 1202.686M | 1043.753M | 1112.584M | 1066.982M | 1085.442M |
| Other Current Liab | 444.299M | 455.083M | 406.226M | 381.869M | 327.242M |
| Common Stock | 1.726M | 1.69M | 1.658M | 1.62M | 1.602M |
| Capital Stock | 1.726M | 1.69M | 1.658M | 1.62M | 1.602M |
| Retained Earnings | -1343.528M | -1699.285M | -1541.018M | -1492.849M | -1381.988M |
| Good Will | 83.027M | 92.873M | 92.873M | 92.873M | 92.873M |
| Other Assets | 0M | 122.393M | 224.915M | 284.692M | 140.079M |
| Cash | 457.469M | 292.473M | 337.544M | 272.961M | 203.771M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 515.678M | 497.742M | 471.286M | 438.258M | 391.112M |
| Current Deferred Revenue | 2.73M | 6.816M | 6.339M | 7.512M | 6.766M |
| Net Debt | -166.739M | 0.797M | -41.74M | 2M | 73.367M |
| Short Term Debt | 3M | 3M | 3M | 2.843M | 2.843M |
| Short Long Term Debt | 3M | 3M | 3M | 2.843M | 2.843M |
| Short Long Term Debt Total | 290.73M | 293.27M | 295.804M | 274.961M | 277.138M |
| Other Stockholder Equity | 2547.598M | 2752.237M | 2655.667M | 2559.56M | 2467.644M |
| Property Plant Equipment | - | 325.361M | 341.054M | 350.003M | 362.168M |
| Total Current Assets | 1431.133M | 1261.916M | 1291.599M | 1135.751M | 1041.361M |
| Long Term Investments | 39.887M | 131.61M | 229.43M | 24.78M | 79.391M |
| Short Term Investments | 316.022M | 315.992M | 198.767M | 362.066M | 331.208M |
| Net Receivables | 333.183M | 296.896M | 326.556M | 289.544M | 265.472M |
| Long Term Debt | 287.73M | 290.27M | 292.804M | 272.118M | 274.295M |
| Inventory | 186.406M | 181.418M | 150.335M | 125.738M | 101.803M |
| Accounts Payable | 65.649M | 32.843M | 55.721M | 46.034M | 54.261M |
| Accumulated Other Comprehensive Income | -3.11M | -10.889M | -3.723M | -1.349M | -1.816M |
| Non Currrent Assets Other | 157.354M | -1.064M | -86.348M | 148.904M | -17.591M |
| Non Current Assets Total | 705.09M | 702.062M | 732.885M | 813.979M | 764.042M |
| Capital Lease Obligations | 81.455M | 105.551M | 120.402M | 135.196M | 13.808M |
| Long Term Debt Total | - | 290.27M | 292.804M | 272.118M | 274.295M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -28.044M | -45.408M | 23.458M | -52.916M | 46.729M |
| Total Cashflows From Investing Activities | -64.541M | -66.204M | -11.481M | -141.833M | -22.195M |
| Total Cash From Financing Activities | -1.574M | 29.072M | -2.171M | 6.765M | -1.62M |
| Net Income | -158.267M | -48.169M | -110.861M | -196.62M | -139.311M |
| Change In Cash | -45.071M | 64.583M | 69.19M | -62.991M | 75.466M |
| Begin Period Cash Flow | 337.544M | 272.961M | 203.771M | 266.762M | 191.296M |
| End Period Cash Flow | 292.473M | 337.544M | 272.961M | 203.771M | 266.762M |
| Total Cash From Operating Activities | 21.044M | 101.715M | 82.842M | 72.077M | 99.281M |
| Depreciation | 77.862M | 78.652M | 81.854M | 80.413M | 103.66M |
| Other Cashflows From Investing Activities | 1.758M | 7.224M | 7.28M | 2.025M | 0.507M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -31.021M | -24.769M | -22.933M | -13.077M | -2.665M |
| Sale Purchase Of Stock | 19.63M | 25.319M | 8.373M | 18.925M | 20.877M |
| Other Cashflows From Financing Activities | 1.426M | 31.322M | 0.672M | 9.608M | 0.512M |
| Capital Expenditures | 38.255M | 29.02M | 42.219M | 90.942M | 69.431M |
| Change In Working Capital | 12.709M | -25.548M | 13.131M | 65.406M | -7.42M |
| Other Non Cash Items | 27.281M | 4.077M | -1.431M | 22.22M | 26.372M |
| Free Cash Flow | -17.211M | 72.695M | 40.623M | -18.865M | 29.85M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | iShares Core S&P Small-Cap ETF | 6 months ago | 10663211 |
| 2. | Vanguard Health Care Inv | 8 months ago | 8601892 |
| 3. | T. Rowe Price US Mid-Cap Value Equity | 8 months ago | 5623658 |
| 4. | T. Rowe Price Mid-Cap Value | 7 months ago | 5376677 |
| 5. | Vanguard Total Stock Mkt Idx Inv | 7 months ago | 5131906 |
| 6. | iShares Russell 2000 ETF | 6 months ago | 4577172 |
| 7. | Vanguard Small Cap Index | 7 months ago | 4130163 |
| 8. | Pacer US Small Cap Cash Cows 100 ETF | 6 months ago | 4034710 |
| 9. | T. Rowe Price U.S. Mid-Cap Val Eq Tr-Z | 8 months ago | 2967714 |
| 10. | SPDR® S&P Biotech ETF | 6 months ago | 2749532 |
| 11. | Vanguard Institutional Extnd Mkt Idx Tr | 7 months ago | 2456901 |
| 12. | Vanguard Small Cap Growth Index Inv | 7 months ago | 2270701 |
| 13. | Avantis US Small Cap Value ETF | 6 months ago | 2049924 |
| 14. | Vanguard Capital Opportunity Inv | 8 months ago | 1837600 |
| 15. | Fidelity Small Cap Index | 8 months ago | 1664776 |
| 16. | SPDR® Portfolio S&P 600™ Sm Cap ETF | 6 months ago | 1503297 |
| 17. | iShares Russell 2000 Growth ETF | 6 months ago | 1484959 |
| 18. | Vanguard Explorer Inv | 8 months ago | 1434086 |
| 19. | First Trust NYSE Arca Biotech ETF | 6 months ago | 1351310 |
| 20. | Pictet Biopharmaceutical Mother | 1 year ago | 1267956 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | T. Rowe Price Associates, Inc. | 8 months ago | 12998606 |
| 2. | Wellington Management Company LLP | 8 months ago | 12658245 |
| 3. | State Street Corp | 8 months ago | 9185392 |
| 4. | RTW INVESTMENTS, LLC | 8 months ago | 6654033 |
| 5. | Renaissance Technologies Corp | 8 months ago | 5421031 |
| 6. | Baker Bros Advisors LP | 8 months ago | 4181751 |
| 7. | Pacer Advisors, INC. | 8 months ago | 4165390 |
| 8. | Geode Capital Management, LLC | 8 months ago | 3873927 |
| 9. | Deep Track Capital, LP | 8 months ago | 3500000 |
| 10. | PRIMECAP Management Company | 8 months ago | 3297115 |
| 11. | BlackRock Inc | 11 months ago | 29107548 |
| 12. | Vanguard Group Inc | 8 months ago | 18971637 |
| 13. | American Century Companies Inc | 8 months ago | 3240967 |
| 14. | Morgan Stanley - Brokerage Accounts | 8 months ago | 2569333 |
| 15. | Bank of New York Mellon Corp | 8 months ago | 2192970 |
| 16. | NORGES BANK | 11 months ago | 2128943 |
| 17. | Charles Schwab Investment Management Inc | 8 months ago | 2107049 |
| 18. | Artisan Partners Limited Partnership | 8 months ago | 1938326 |
| 19. | COMMODORE CAPITAL LP | 8 months ago | 2900000 |
| 20. | Dimensional Fund Advisors, Inc. | 8 months ago | 2890807 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...